Đang chuẩn bị liên kết để tải về tài liệu:
Study protocol of a phase II study to evaluate safety and efficacy of neo-adjuvant pembrolizumab and radiotherapy in localized rectal cancer

Đang chuẩn bị nút TẢI XUỐNG, xin hãy chờ

Reshaping the tumor microenvironment by novel immunotherapies represents a key strategy to improve cancer treatment. Nevertheless, responsiveness to these treatments is often correlated with the extent of T cell infiltration at the tumor site. Remarkably, microsatellite stable rectal cancer is characterized by poor T cell infiltration and, therefore, does not respond to immune checkpoint blockade. |

TÀI LIỆU LIÊN QUAN

The WIRE study a phase II, multi-arm, multicentre, non-randomised window-ofopportunity clinical trial platform using a Bayesian adaptive design for proof-ofmechanism of novel treatment strategies in operable renal cell cancer – a study protocol

A randomized phase II study of S-1 monotherapy versus cisplatin with vinorelbine for completely resected stage II/IIIA non-small cell lung cancer: Rationale and study protocol design for the LOGIK1702 study

Enzalutamide versus flutamide for castration-resistant prostate cancer after combined androgen blockade therapy with bicalutamide: Study protocol for a multicenter randomized phase II trial (the OCUU-CRPC study)

Treatment using oxaliplatin and S-1 adjuvant chemotherapy for pathological stage III gastric cancer: A multicenter phase II study (TOSA trial) protocol

A phase II JN-I-10 efficacy study of IDRF-based surgical decisions and stepwise treatment intensification for patients with intermediate-risk neuroblastoma: A study protocol

Protocol for the 2ND-STEP study, Japan Clinical Oncology Group study JCOG1802: A randomized phase II trial of second-line treatment for advanced soft tissue sarcoma comparing trabectedin, eribulin and pazopanib

Neoadjuvant chemoradiotherapy plus tislelizumab followed by surgery for esophageal carcinoma (CRISEC study): The protocol of a prospective, single-arm, phase II trial

ELEVATE – evaluating Temozolomide and Nivolumab in patients with advanced unresectable previously treated oesophagogastric adenocarcinoma with MGMT methylation: Study protocol for a single arm phase II trial

Daily irradiation versus irradiation at two- to three-day intervals in stereotactic radiotherapy for patients with 1-5 brain metastases: Study protocol for a multicenter open-label randomized phase II trial

Study protocol for an open-label, singlearm, phase Ib/II study of combination of toripalimab, nab-paclitaxel, and gemcitabine as the first-line treatment for patients with unresectable pancreatic ductal adenocarcinoma